US00287Y1091
US00287Y1091
AbbVie Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 488.55B EUR | 444.67B EUR | 384.25B EUR | 403.94B EUR |
Enterprise Value | 545.76B EUR | 508.92B EUR | 447.71B EUR | 466.21B EUR |
Valuation Multiples | ||||
Trailing P/E | 78.1x | 70.47x | 105.71x | 137.4x |
Forward P/E | 17x | -- | -- | -- |
Price to Sales | 7.59x | 6.91x | 6.12x | 8.45x |
Price to Book | -- | -- | -- | -- |
EV/Revenue | 8.48x | 7.9x | 7.13x | 9.75x |
EV/EBITDA | 17.74x | 20.78x | 19.93x | 25.86x |
Price to FCF (P/FCF) | 28.96x | 24.42x | 19.23x | 24.61x |
EV/FCF | 32.35x | 27.95x | 22.41x | 28.4x |
FCF Yield | 3.45% | 4.1% | 5.2% | 4.06% |